These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15592836)

  • 1. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group.
    Judson I; Ma P; Peng B; Verweij J; Racine A; di Paola ED; van Glabbeke M; Dimitrijevic S; Scurr M; Dumez H; van Oosterom A
    Cancer Chemother Pharmacol; 2005 Apr; 55(4):379-386. PubMed ID: 15592836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
    Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.
    Schmidli H; Peng B; Riviere GJ; Capdeville R; Hensley M; Gathmann I; Bolton AE; Racine-Poon A;
    Br J Clin Pharmacol; 2005 Jul; 60(1):35-44. PubMed ID: 15963092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC.
    van Erp N; Gelderblom H; van Glabbeke M; Van Oosterom A; Verweij J; Guchelaar HJ; Debiec-Rychter M; Peng B; Blay JY; Judson I
    Clin Cancer Res; 2008 Dec; 14(24):8308-13. PubMed ID: 19088049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.
    Delbaldo C; Chatelut E; Ré M; Deroussent A; Séronie-Vivien S; Jambu A; Berthaud P; Le Cesne A; Blay JY; Vassal G
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6073-8. PubMed ID: 17062683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients.
    Eechoute K; Fransson MN; Reyners AK; de Jong FA; Sparreboom A; van der Graaf WT; Friberg LE; Schiavon G; Wiemer EA; Verweij J; Loos WJ; Mathijssen RH; De Giorgi U
    Clin Cancer Res; 2012 Oct; 18(20):5780-7. PubMed ID: 22850565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group.
    van Oosterom AT; Judson IR; Verweij J; Stroobants S; Dumez H; Donato di Paola E; Sciot R; Van Glabbeke M; Dimitrijevic S; Nielsen OS;
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S83-7. PubMed ID: 12528778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.
    Petain A; Kattygnarath D; Azard J; Chatelut E; Delbaldo C; Geoerger B; Barrois M; Séronie-Vivien S; LeCesne A; Vassal G;
    Clin Cancer Res; 2008 Nov; 14(21):7102-9. PubMed ID: 18981009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.
    Widmer N; Decosterd LA; Csajka C; Leyvraz S; Duchosal MA; Rosselet A; Rochat B; Eap CB; Henry H; Biollaz J; Buclin T
    Br J Clin Pharmacol; 2006 Jul; 62(1):97-112. PubMed ID: 16842382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?
    von Mehren M; Widmer N
    Cancer Treat Rev; 2011 Jun; 37(4):291-9. PubMed ID: 21078547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of advanced gastrointestinal stromal tumors in patients over 75 years old: clinical and pharmacological implications.
    Italiano A; Saada E; Cioffi A; Poulette S; Bouchet S; Molimard M; Adenis A; Isambert N; Collard O; Le Cesne A; Maki RG; Bui B
    Target Oncol; 2013 Dec; 8(4):295-300. PubMed ID: 23263874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.
    Koo DH; Ryu MH; Ryoo BY; Beck MY; Na YS; Shin JG; Lee SS; Kim EY; Kang YK
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):173-82. PubMed ID: 25417047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor.
    Trent JC; Ramdas L; Dupart J; Hunt K; Macapinlac H; Taylor E; Hu L; Salvado A; Abbruzzese JL; Pollock R; Benjamin RS; Zhang W
    Cancer; 2006 Oct; 107(8):1898-908. PubMed ID: 16986125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib.
    Yoo C; Ryu MH; Kang BW; Yoon SK; Ryoo BY; Chang HM; Lee JL; Beck MY; Kim TW; Kang YK
    J Clin Oncol; 2010 Mar; 28(9):1554-9. PubMed ID: 20177019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.
    Teng JF; Mabasa VH; Ensom MH
    Ther Drug Monit; 2012 Feb; 34(1):85-97. PubMed ID: 22215488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.
    Demetri GD; Wang Y; Wehrle E; Racine A; Nikolova Z; Blanke CD; Joensuu H; von Mehren M
    J Clin Oncol; 2009 Jul; 27(19):3141-7. PubMed ID: 19451435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of pharmacokinetic studies for patients with gastrointestinal stromal tumors.
    De Giorgi U
    Future Oncol; 2013 Nov; 9(11):1675-7. PubMed ID: 23862700
    [No Abstract]   [Full Text] [Related]  

  • 18. Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs).
    Rutkowski P; Nowecki ZI; Debiec-Rychter M; Grzesiakowska U; Michej W; Woźniak A; Siedlecki JA; Limon J; vel Dobosz AJ; Kakol M; Osuch C; Ruka W
    J Cancer Res Clin Oncol; 2007 Sep; 133(9):589-97. PubMed ID: 17458563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.
    Verweij J; van Oosterom A; Blay JY; Judson I; Rodenhuis S; van der Graaf W; Radford J; Le Cesne A; Hogendoorn PC; di Paola ED; Brown M; Nielsen OS
    Eur J Cancer; 2003 Sep; 39(14):2006-11. PubMed ID: 12957454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New strategies for treating GIST when imatinib fails.
    Boyar MS; Taub RN
    Cancer Invest; 2007 Aug; 25(5):328-35. PubMed ID: 17661208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.